Bedrijfsoverzicht
Citius Pharmaceuticals, Inc. is a biopharmaceutical entity dedicated to the development and commercialization of critical care products, with a specific focus on targeted immunotherapies for conditions such as cutaneous T-cell lymphoma. The company operates within the healthcare sector, specifically inside the biotechnology industry, which implies a high-risk, high-reward environment focused on research and innovation rather than established manufacturing. Currently, the organization employs 23 individuals and holds a total market capitalization of $18.01 million, while generating annual revenue of $3.94 million. These financial figures indicate that the company is a micro-cap entity with a relatively small operational footprint, suggesting it is in an early-to-mid stage of commercialization where revenue generation is currently limited compared to larger peers. The combination of a modest revenue stream and a market cap under $20 million highlights that the company's current value is primarily driven by its pipeline assets rather than established cash flows.
Financiële gezondheid
The company reported revenue of $3.94 million over the trailing twelve months, yet it recorded a net income of $-35,886,448, revealing a significant gap between top-line sales and bottom-line profitability that points to substantial operational costs or research and development expenses consuming the majority of generated revenue. This negative net income is further reflected in an EBITDA of $-36,357,252, which underscores that the company is burning cash to fund its scientific endeavors rather than generating positive operating earnings. The free cash flow stands at $-40,525,064, indicating that the company has limited financial flexibility and relies heavily on external capital markets or existing reserves to fund its ongoing operations and development programs. Regarding margins, the gross margin is 80.0%, which suggests high efficiency in production costs for its approved products, whereas the operating margin of -214.1% and profit margin of 0.0% demonstrate severe losses relative to sales due to high overheads or R&D expenditures. On the balance sheet, the company holds $7.72 million in cash against $1.83 million in debt, resulting in a debt-to-equity ratio of 1.96, which suggests a leveraged position despite having more cash on hand than debt outstanding. The current ratio is 0.99, indicating that the company's current assets are nearly equal to its current liabilities, which presents a tight liquidity position where short-term assets may be insufficient to cover short-term obligations without additional financing. Return on Equity is -47.9% and Return on Assets is -17.7%, metrics that reveal that management has not yet been effective in generating returns on the capital invested, a typical characteristic for pre-profitability biotechnology firms.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is N/A due to negative earnings, while the forward P/E is listed as 0.29, a disparity that implies the market is valuing the company based on future expectations of earnings recovery rather than historical performance. The price-to-book ratio stands at 0.23, indicating that the market values the company at significantly less than its book value, which often reflects skepticism about the recoverability of assets or the value of the unproven pipeline. Alternative valuation metrics show a price-to-sales ratio of 4.57 and an EV/EBITDA of -0.70, suggesting that investors are pricing the stock based on revenue multiples and the company's ability to eventually transition from negative EBITDA to profitability. The stock has traded between a 52-week low of $0.63 and a 52-week high of $2.48, meaning the current price sits at a level that reflects significant volatility within this defined trading range. With a beta of 1.38, the stock exhibits higher volatility than the broader market, meaning its price is expected to swing more aggressively than the overall market index in response to sector-specific news or general market movements.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, indicating that historical growth rates cannot be calculated or are not currently applicable given the company's recent financial history. Since the company does not pay a dividend, there is no dividend yield or payout ratio to analyze, meaning the company reinvests all available earnings and cash reserves directly back into its research, development, and commercialization efforts rather than distributing income to shareholders. The overall growth and income profile is characterized by a lack of current profitability and dividend income, with the company's value proposition resting entirely on the potential future success of its late-stage pipeline assets like Mino-Lok and its approved product LYMPHIR.